MindWalk Holdings Corp.™ (Nasdaq: HYFT), a Bio-Native AI company based in Austin, Texas, has announced a major breakthrough in its GLP-1 therapeutics program, leveraging its proprietary AI platform LensAI™ to uncover a novel dual-pathway approach to longevity medicine. The company revealed that its AI-driven analysis identified a previously unknown biological pathway that works independently of GLP-1 signaling but is central to healthy aging, systemic resilience, and metabolic balance. This discovery forms the foundation of a first-in-class regimen in which MindWalk’s AI-designed GLP-1 receptor agonists (GLP-1RAs) are co-administered with a proprietary companion therapeutic, targeting both pathways simultaneously. To the company’s knowledge, no approved or marketed drugs currently use this dual-pathway strategy. The companion therapeutic is a wholly original, MindWalk-exclusive asset, not a repurposed or co-branded product. This advancement builds on the company’s earlier success in designing GLP-1RAs entirely in silico using its patented HYFT® first-principles discovery engine. Earlier this year, MindWalk reported that its AI-designed GLP-1 peptides matched or exceeded semaglutide—currently a global market leader—in receptor activation assays, demonstrating the platform’s ability to deliver high-performance candidates without traditional trial-and-error methods. The key innovation lies in LensAI™’s ability to map conserved biological patterns across sequence, structure, and function. By integrating sequence models, structural predictions, and knowledge-graph reasoning, the platform identified a second regulatory node that complements GLP-1 activity in regulating inflammation, cellular stress response, and metabolic health. This dual engagement aims to enhance the durability and quality of GLP-1 signaling while broadening therapeutic impact on Healthspan—the period of life spent in good health—beyond traditional glucose control and weight management. Dr. Jennifer Bath, CEO of MindWalk, emphasized that this is not an incremental improvement but a fundamental rethinking of GLP-1 therapeutics. “We are not simply iterating on existing drugs—we are uncovering first principles that enable the design of safe, durable GLP-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway,” she said. The company has already initiated intellectual property protection for both the companion therapeutic and the dual-pathway regimen. The announcement underscores the scalability of MindWalk’s Bio-Native AI platform. The same HYFT®-driven framework is being applied to other high-value therapeutic areas, including oncology, immunology, and vaccine design, enabling a multi-program pipeline built on a single, explainable AI foundation. Unlike black-box AI tools, LensAI™ offers full biological traceability and lineage tracking, which are critical for regulatory review and clinical development. MindWalk’s platform combines computational discovery with an integrated wet lab, enabling rapid translation from insight to validated candidate. The company has already advanced its dual-pathway program into preclinical development, with updates on lead selection, combination design, and development strategy expected in the coming quarters. The longevity therapeutics market, projected to exceed $60 billion by 2030, is a major growth frontier. MindWalk’s AI-first approach positions it to lead in this space by delivering scientifically grounded, repeatable, and scalable drug discovery. The company continues to collaborate with leading biopharma partners and expand its pipeline across modalities. Forward-looking statements in the announcement include expectations around the development of the dual-pathway regimen, the benefits of HYFT® and LensAI™, and the platform’s broader applications. These are subject to risks in drug development, regulatory approval, competition, and intellectual property, as detailed in the company’s filings. MindWalk’s latest milestone highlights how AI is transforming drug discovery—not just by accelerating it, but by uncovering new biological truths that were previously inaccessible.